ArticleOncotarget2016

The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.

Mike I Walton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.